SEC Form 4												
FORM 4	UNITED ST	INITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	• • • • •		F CHANGES nt to Section 16(a) c ction 30(h) of the Inv						ווי	OMB Number: Estimated average hours per respons	11	
1. Name and Address of Reporting Person <sup>*</sup> Gould Terry P			2. Issuer Name and Ticker or Trading Symbol <u>Corvus Pharmaceuticals, Inc.</u> [ CRVS ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner			
(Last) (First) C/O CORVUS PHARMACEUT	1	3. Date of Earliest Transaction (Month/Day/Year) Officer (give title below) Other (specified)   08/11/2022 08/11/2022 08/11/2022 08/11/2022										
863 MITTEN ROAD, SUITE 102 (Street)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person			
BURLINGAME CA	94010	_							Form filed by More than One Reporting Person			
(City) (State)	(Zip)											
	Table I - Non-Der	vative S	ecurities Acqu	uired,	Disp	posed of, o	or Ben	eficially	Owned			
Date		ansaction hth/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		l (A) or . 3, 4 and	5. Amount of Securities Beneficially Owned Followi	6. Owners Form: Dire (D) or India ng (I) (Instr. 4)	ect Indirect rect Beneficial ) Ownership	
				Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock, \$0.0001 par valu	le								3,275,616	5 I	By Funds <sup>(1)(2)</sup>	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 3. Transaction 5. Number 6. Date Exercisable and 7. Title and Amount 9. Number of 11. Nature 1. Title of 3A. Deemed Execution Date. 8. Price of Derivative 10. 2. Conversion Date Derivative Transaction of Expiration Date of Securities derivative Ownership of Indirect if any (Month/Day/Year) (Month/Day/Year) Security (Instr. 3) or Exercise Price of (Month/Day/Year) Code (Instr. 8) Derivative Underlying Derivative Security Security (Instr. 5) Securities Beneficially Form: Direct (D) Beneficial Ownership Securities Derivative Acquired (Instr. 3 and 4) Owned or Indirect (Instr. 4) (A) or Disposed Security Following (I) (Instr. 4) Reported of (D) (Instr. 3, 4 and 5) Transaction(s) (Instr. 4) Amount Number Date Expiration v (A) (D) Title Shares Code Exercisable Date Stock Option Commo \$0.965 08/11/2022 A 15,000 (3) 08/11/2032 15,000 \$0.00 15,000 **D**<sup>(4)</sup> (Right to Stock Buy)

## Explanation of Responses:

1. Represents 694,854 shares held by Adams Street 2011 Direct Fund LP ("AS 2011"), 715,361 shares held by Adams Street 2012 Direct Fund LP ("AS 2012"), 541,133 shares held by Adams Street 2013 Direct Fund LP ("AS 2013"), 736,033 shares held by Adams Street 2014 Direct Fund LP ("AS 2014"), 69,864 shares held by Adams Street 2015 Direct Venture/Growth Fund LP ("AS 2015"), 67,769 shares held by Adams Street 2016 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held by Adams Street 2017 Direct Venture/Growth Fund LP ("AS 2017"), 126,806 shares held by Adams Street 2018 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held by Adams Street 2017 Direct Venture/Growth Fund LP ("AS 2017"), 126,806 shares held by Adams Street 2018 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held by Adams Street 2017 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held by Adams Street 2017 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held by Adams Street 2017 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held by Adams Street 2017 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held by Adams Street 2017 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held by Adams Street 2017 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held by Adams Street 2017 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held by Adams Street 2018 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held by Adams Street 2018 Direct Venture/Growth Fund LP ("AS 2016"), 87,678 shares held by Adams Street 2018 Direct Venture/Growth Fund LP ("AS 2016"), 87,678 shares held by Adams Street 2018 Direct Venture/Growth Fund LP ("AS 2016"), 87,678 shares held by Adams Street 2018 Direct Venture/Growth Fund LP ("AS 2016"), 87,678 shares held by Adams Street 2018 Direct Venture/Growth Fund LP ("AS 2016"), 87,678 shares held by Adams Street 2018 Direct Venture/Growth Fund LP ("AS 2016"), 87,678 shares held by Adams Street 2018 Direct Venture/Growth Fund LP ("AS 2016"), 87,678 shar Venture/Growth Fund LP ("AS 2018") and 236,128 shares held by Adams Street Venture/Growth VI LP ("ASVG VI").

2. Adams Street Partners, LLC, as the managing member of the general partner of the general partner of each of AS 2011, AS 2012, AS 2013, AS 2014, AS 2015, AS 2016, AS 2017, AS 2018 and ASVG VI (collectively the "Funds"), may be deemed to beneficially own the shares held by the Funds. Thomas S. Brenner, Jeffrey T. Diehl, Brian Dudley, Elisha P. (Terry) Gould, Robin Murray and Fred Wang, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares held by the Funds. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Brian Dudley, Elisha P. Gould, Robin Murray and Fred Wang disclaim beneficial ownership of the shares held by the Funds except to the extent of their pecuniary interest therein.

3. The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

4. This option was granted to Elisha P. Gould, a director of Corvus Pharmaceuticals, Inc., who is a partner of Adams Street Partners, LLC. Adams Street Partners, LLC is the managing member of the general partner of the general partner of each of the Funds. By agreement with the Funds, MLC Gould is deemed to hold the option for the benefit of the Funds, MLC address the fund of the general partner of each of the Funds. By agreement with the Funds, MLC Gould is deemed to hold the option for the benefit of the Funds. The option may be deemed to be indirectly beneficially owned by Adams Street Partners, LLC. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Brian Dudley, Elisha P. Gould, Robin Murray and Fred Wang, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), disclaim beneficial ownership of the option except to the extent of the pecuniary interest therein.

/s/ Leiv Lea, as Attorney-in- Fact for Terry P. Gould	08/15/2022
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.